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Abstract 
Connectivity mapping is the process of establishing connections between different 
biological states using gene expression profiles or signatures. There are a number of 
applications but in toxicology the most pertinent is for understanding mechanisms of 
toxicity. In its essence the process involves comparing a query gene signature generated 
as a result of exposure of a biological system to a chemical to those in a database that 
have been previously derived. In the ideal situation the query gene expression signature is 
characteristic of the event and will be matched to similar events in the database. Key 
criteria are therefore the means of choosing the signature to be matched and the means by 
which the match is made. In this article we explore these concepts with examples 
applicable to toxicology. 
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What is connectivity mapping? 
The concept of connectivity mapping was first introduced by Lamb et al in 2006 (Lamb 
et al., 2006). It sought to make association between gene expression due to disease state 
and that due to drug molecules, or similarly between disease state and gene alteration. In 
making the connections the purpose is to identify molecules which may be used in the 
treatment of disease, or genes that are the underlying cause. The premise of the methods 
is that different biological states can be described or characterized adequately using a 
genomic signature, e.g. the genome-wide mRNA levels as measured by the microarray 
technologies. The biological connection between two states can then be established by 
comparing the genomic signatures that represent them based on their signature similarity. 
In these comparisons similarity is as valuable as diversity. For example if the gene-
expression signature of a small-molecule compound is found to be opposite that of a 
disease state, in other words, the key set of genes are oppositely regulated in the two 
biological states, then the compound might be used as a drug to treat the disease. Another 
application of connectivity mapping is to discern properties in a new chemical entity 
(NCE) by finding positive (or negative for an antagonist) connections with the database 
of reference compounds. It is this latter application that allows the use of connectivity 
mapping to make valid predictions on the toxicological properties of a compound if a 
gene-expression signature for that compound can be obtained. In principal, two 
compounds may be recognized as having similar toxicological (and/or pharmacological) 
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properties even if they primarily target different genes of some biological pathway(s) but 
nevertheless affect a common set of downstream genes similarly.   
 
There are three key components in connectivity mapping: 1. A large collection of pre-
built reference gene-expression profiles that serves as a core database, in which each 
reference profile characterizes a well-defined biological state. 2. A query gene signature 
that a researcher has compiled as a result of microarray experiments investigating a 
particular biological condition. 3. A pattern matching algorithm or similarity metric that 
quantifies the connection between a query gene signature and a reference profile. So a 
connectivity score is defined as a function between a query gene signature and a 
reference profile in such a way that it should reflect the underlying biological 
connections. If the genes in the query signature are similarly regulated in a reference 
profile, this indicates a strong positive connection between the query gene signature and 
the reference profile. If, on the other hand, the genes in a signature are oppositely 
regulated in a reference profile, there is a negative connection between the two.  As we 
already mentioned earlier, a negative connection between a drug-induced gene-
expression profile, and a disease gene signature suggest that this drug might be useful to 
treat the disease.     
A connectivity map with practical utility thus must have a core database of reference 
gene-expression profiles. The first attempt to build such a database was made by 
researchers in the Broad Institute of MIT and Harvard (http://www.broad.mit.edu/cmap/). 
In their Connectivity Map Build 01, 164 bioactive small-molecule compounds were 
applied to 5 selected human cell lines (MCF7, PC3, SKMEL5, HL60, and ssMCF7)  
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resulting in 564 Affymetrix microarrays, which provided data for 453 individual 
reference gene-expression profiles. The latest release of Connectivity Map Build 02 of 
Broad Institute include transcriptomics data of 1309 small-molecule compounds applied 
to the same 5 selected human cell lines, with 7056 Affymetrix microarrays for 6100 
individual reference profiles.  
 
 
Examples of success 
The utility of connectivity mapping was demonstrated previously using some 
experimentally derived query gene signatures from independent studies, e.g., for HDAC 
inhibitors (Glaser et al., 2003), estrogen (Frasor et al., 2004), and immunosuppressive 
drugs (Horwitz  et al.,  2004). For the HDAC inhibitors query gene signature, vorinostat, 
trichostatin A,  valproic acid, and HC-toxin were found to have significant positive 
connections to the signature, which were in accordance with the known properties of 
these compounds as HDAC inhibitors. For the immunosuppressive drugs query gene 
signature, the identified positive connections include azathioprine (Armstrong et al., 
2001; Matalon et al., 2004), thalidomide (McHugh et al., 1995), staurosporine (Ting et 
al., 1995),  and trichostatin A (Januchowski et al., 2007), the immunosuppressive 
properties of which were all shown in the corresponding references.  
 
Estrogen gene signature: The Estrogen Receptor (ER) is a group of receptor proteins 
that are activated by estrogen. The main function of the ER is its gene-regulatory role as a 
DNA-binding transcription factor. Thus by treating ER positive cells with estrogen, the 
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ERs are activated to regulate downstream gene expression, and this event results in a 
gene-expression profile characteristic of the event. We have used an estrogen query gene 
signature to demonstrate the success of connectivity mapping (Zhang and Gant, 2008). 
The collection of reference gene-expression profiles were based on the public dataset of 
the Broad Institute Connectivity Map Build 01 with 453 individual reference gene-
expression profiles in total. The query gene signature for estrogen was based on an 
independent study (Frasor et al., 2004) where the MCF7 human breast cancer cell line 
was treated with the natural estrogen receptor ligand estradiol. The resulting query gene 
signature included 40 up-regulated and 89 down-regulated genes as selected by the 
authors of the original study. When the estrogen signature was compared with the 
database of 453 reference profiles, the following compounds in the database were shown 
to have significant positive connections with estrogen: Estradiaol, alpha-estradiol, 
genistein, and NDGA, indicating that these may have similar estrogen receptor binding 
properties as estrogen. In this example estradiol acted as a test of the method because 
reference profiles for this compound were known to be present in the database. Therefore 
the positive connection with estrogen signature was reassuring. The other connections 
made were also biologically plausible, alpha-estradiol is a stereoisomer of estradiol 
(Edwards and McGuire, 1980) and genistein is a phyto-estrogen (de Lemos, 2001) from 
plants. However NDGA was an unexpected finding, at least to us, as we were not aware 
of NDGA to be an ER related compound. Therefore the question for NDGA was, if it is 
connected positively with estrogen is there any other support for this in the literature? A 
text search showed that this was indeed a plausible connection and some references show 
that NDGA has an estrogenic activity and able to elicit an estrogen-like response 
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(Fujimoto et al., 2004; Sathyamoorthy et al., 1994).  There were also significant negative 
connections and these compounds were antagonists of the estrogen receptor. These 
negatively correlated compounds included the well known estrogen receptor antagonists 
fulvestrant, tamoxifen, and raloxifene (Buzdar, 2004; Jacobs et al., 1988; Fuchs-Young et 
al., 1995).   
 
Pumaprazole gene signature: PredTox is an EU 6th Framework Programme 
(http://www.innomed-predtox.com) carried out by a consortium of 14 pharmaceutical 
companies, 3 academic institutions and 2 technology providers. The primary aim of the 
consortium was to provide the data generated from all the ‘omics technologies in addition 
to results from more conventional toxicology methods, to identify new biomarkers with 
utility for the early identification of toxicity. In the process it also allowed the 
development of more effective ‘omics related analysis techniques for potential use in 
drug discovery and development. The samples in the PredTox study were generated from 
16 compounds which were tested separately by the partners of the consortium following a 
common experimental design and treatment schedule. The compounds used included two 
reference compounds, a hepatotoxin troglitazone and a nephrotoxin, gentamycin. The 
other 14 compounds were drug molecules that had failed early on in development due to 
hepatic or nephrotoxic effects. The PredTox database therefore contains toxicological 
data for 16 compounds tested on rats following a common experimental and treatment 
design. Transcriptomics profiling data were available for the liver, kidney, and blood 
samples of each rat. 
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We first tried to use the liver transcriptomics data for compound FP008AL (pumaprazole) 
to compile a query gene signature and compared it with the collection of reference 
profiles based on the Broad Institute Connectivity Map Build 02 dataset. The 
connectivity mapping exercise using this query gene signature produced significant 
connections with approximately 100 compounds.  The connections made either seemed to 
be related to disruption of glutathione metabolism or the competition with ATP at ATP 
binding sites, mainly those of the ATP-binding cassette (ABC) transporters.  
Lansoprazole was one such compound linked by the latter mechanism. 
 
Lansoprazole is one of the class of drugs known as PPI (proton pump inhibitors), whose 
main pharmacological action is a pronounced and long-lasting reduction of gastric acid 
production (Berlin et al., 1992).  The FP008AL compound in the PredTox study is 
pumaprazole, a reversible proton pump inhibitor (Martínek et al., 1999). The connection 
between these proton pump inhibitors was a very significant one for verification of the 
analysis technique, and its significance notable for the following reasons: 1. This was a 
cross-species comparison, as the query gene signature was based on rat data, while the 
collection of reference profiles were based on human data. 2. The query gene signature 
was based on in-vivo data, while the reference profiles were in vitro data. 3. Unlike the 
estrogen receptor, the proton pump is not known as a transcription factor. It therefore 
does not directly regulate transcriptional gene expression as  does estrogen receptor. It is 
therefore all the more significant that a gene expression profile which would have 
resulted from an indirect effect of the compound on cellular biochemistry has sufficient 
identity to allow matching with a similar compound across organs, in vivo to in vitro and 
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species. Therefore despite these 3 apparent barriers to success, the connectivity map was 
still able to pick up the connection between the pumaprazole query gene signature and the 
lansoprazole reference profile. This example indicates therefore the power of this 
analytical method.   
 
Predictive toxicity 
Next we tried to use the 16 transcriptomics datasets from the PredTox study to construct 
reference gene-expression profiles against which to match a query gene signature from 
another study.  If all the data were available there would be 288 individual reference 
profiles [288 combinations of 16 compounds, 2 doses (low and high apart from vehicle 
control), 3 time points (day 2, 4, and 15), and 3 tissue types (liver, kidney and blood)]. 
Some of the data were not available on the PredTox database but with that which were 
available, we constructed over 250 reference gene-expression profiles each is named 
according to its derivation, e.g. FP001RO_LowDose_Liver_Day04, where the compound 
code is first, followed by dose, tissue and time point.  
 
To compare against this collection of PredTox reference profiles, we compiled some 
query gene signatures from mice treated with the compound griseofulvin. Griseofulvin is 
an antifungal drug that causes a cholestasis on oral administration due to an irrevsible 
inhibition of the terminal enzyme of haem biosynthesis in the liver ferrochelatase (Polo et 
al., 1997; Gant et al., 2003). This causes an accumulation of protoporphyrin IX in the 
liver which blocks bile canaliculi leading to cholestasis. In the study (Gant et al., 2003)  
C57BL/6J and BALB/c mice were treated with 1% griseofulvin administered in the diet 
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over a time course with sampling at days 1, 3, 5, 8, 15 and 21.  For each time point there 
were 4 pairs of mice and microarray analysis was carried out on liver samples from each 
time point. From the data we compiled 7 query gene signatures using C57BL/6J and 
BALB/c mice transcription data. We found that on average, each query gene signature 
has significant connections to 30 reference profiles in the PredTox collection. In this 
connectivity mapping exercise, the threshold p-value was set such that on average 1 false 
connection was expected per query signature, so the overall FDR (False Discovery Rate) 
was estimated as 3.3%.  Detailed descriptions of how p-values were calculated and how 
threshold was set can be found in (Zhang and Gant, 2008).  We note here that it is still 
difficult  to effectively estimate the False Negative Rate (FNR), as this will require a 
power function for the statistical test used in the connectivity mapping exercise, for 
which statistical advancement is still lagging behind. In this exercise, when queried with 
the griseofulvin BALB/c day 1 signature, the connectivity map produced statistically 
significant positive connections with 5 compounds in the PredTox database, and all the 
reference profiles were liver samples and 3 of which were early time points. Of the 5 
compounds found connected to the BALB/c day 1 signature, compounds FP003SE and 
FP008AL belonged to a subgroup, in which hypertrophy in the liver was the major 
histopathological finding;  and compounds FP005ME and FP014SC belonged to a 
subgroup, whose classical common findings were bile duct damage, hyperplasia, 
increased bilirubin and cholestasis, much of the effects listed here were also observed in 
the griseofulvin-treated BALB/c mice (Gant et al., 2003).  It is worth noting the 
following points: 1. An early time point gene signature for griseofulvin is most likely to 
contain genes associated with its primary biochemical effect because later as pathology 
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develops much of the differential gene expression is not due to the compound per se but 
rather the pathophysiological response.  2. The data presented here indicates that, in the 
case of cholestasis, connectivity analysis could potentially be used to analyse and predict 
the toxic mechanism of a compound. 3. Significant connections were made despite the 
query gene signature being mouse derived, and the reference profiles being rat derived. 
 
Software 
Implementing the improved methodology of connectivity mapping we introduced in 
(Zhang and Gant 2008), sscMap is an extensible java application for connecting small-
molecule drugs using gene expression signatures (Zhang and Gant 2009). The benefits of 
the method implemented in this application include a more principled statistical 
procedure (Tian et al., 2005; Efron and Tibshirani 2007; Chen et al., 2007), effective 
safeguards against false connections, and an increased sensitivity. The software is 
bundled with a default collection of 6100 reference profiles based on the Broad Institute 
Connectivity Map 02 dataset.  It comes with a user-friendly GUI (Graphical User 
Interface) and detailed tutorial guided instructions for using the program. Users can 
extend the default collection of reference profiles by adding custom-built reference 
profiles to sscMap.  The software can be freely downloaded from  
http://purl.oclc.org/NET/sscMap. 
 
Conclusions 
Recognition of toxicity at early stage, preferably in vitro and if in vivo before the 
development of pathological change is a highly desirable goal which would lead to better 
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toxicological evaluation at decreased cost. Furthermore the recognition of new drug 
candidates is also a highly desirable objective. The connectivity map presented here and 
in previous papers can assist in the achievement of both of these objectives. In drug 
development it can make connections between molecules according to their 
pharmacological properties even when there is no direct effect of the compound on gene 
expression, i.e., the effects on gene expression are secondary to the compound and relate 
to the altered biological state in the test system. In toxicology the method has 
applicability for the early recognition of potential toxicity in novel molecules with an 
indication of mechanism. Therefore applied in the early stages of toxicological evaluation 
it has the potential not only to identify toxicity in a quantitative manner but also to 
provide a qualitative assessment to the nature of that toxicity. Furthermore the method is 
per se generic and therefore can be applied to all other data types, in particular 
proteomics and metabonomics where enough data is generated to produce a signature.  
The connectivity mapping approach also has a special value in recognizing and predicting 
similar pharmacology and toxicology in compounds with distant structures. It allows 
compounds of different chemical structures to be associated if they do have similar 
pharmacological or toxicological properties. An example was already provided in (Lamb 
et al., 2006) where HC-toxin and valproic acid were identified as HDAC inhibitors 
despite the fact that they are structurally distant from those HDAC inhibitors used to 
generate the query signature.    
 
Notwithstanding the success and promise of connectivity mapping, there are a couple of 
practical issues that need to be addressed before this approach can be widely adopted. 
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One of them is how we interpret the likely large number of connections picked up by the 
connectivity mapping exercise, between compounds in a database and a test substance of 
unknown properties.  For example, the PredTox FP008AL compound (pumaprazole) was 
found to have significant connections to over 100 compounds in the Broad Institute 
Connectivity Map 02 collections. In that example, lansoprazole was highlighted and 
discussed as these two compounds were known to have similar pharmacology.  The 
second closely related issue is, with a real unknown compound how do we prioritize the 
discovered connections and develop new hypotheses, so that we can maximize the 
efficiencies and success in the following-up efforts? These remain to be open questions, 
and will be addressed as the development of connectivity mapping approach continues.  
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